FierceBiotech13h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
Intellia Therapeutics price target lowered to $88 from $94 at Chardan
Chardan lowered the firm’s price target on Intellia Therapeutics (NTLA) to $88 from $94 and keeps a Buy rating on the shares after ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...
FierceBiotech9h
Poseida's HAE therapy edits gene in primate livers and reduces kallikrein protein levels in mice, company says
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.
CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
technologynetworks1d
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
Intellia, from the United States. "For many decades, patients with HAE were faced with a very limited number of treatment ...
BioPharma Dive17d
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.